Difference in the prevalence of subclinical left ventricular impairment among left ventricular geometric pattern in a community-based population.


Journal

Journal of cardiology
ISSN: 1876-4738
Titre abrégé: J Cardiol
Pays: Netherlands
ID NLM: 8804703

Informations de publication

Date de publication:
04 2020
Historique:
received: 19 06 2019
revised: 27 08 2019
accepted: 16 09 2019
pubmed: 10 12 2019
medline: 28 1 2021
entrez: 10 12 2019
Statut: ppublish

Résumé

Left ventricular (LV) hypertrophy is reported to cause LV diastolic dysfunction. This study aimed to examine the prevalence of LV diastolic dysfunction in each group categorized by the geometric pattern of LV hypertrophy in a community-based population. We studied 1260 community-dwelling subjects who experienced no symptoms of obvious heart disease (461 men, 799 women) and who participated in annual health check-ups in a rural Japanese community. The subjects were divided into 4 groups according to LV mass index and relative wall thickness: normal geometry, concentric remodeling, eccentric hypertrophy, and concentric hypertrophy. We investigated the prevalence of LV diastolic dysfunction in the overall and stratified population by LV geometric pattern. LV diastolic function was determined by 3 echocardiographic parameters of LV diastolic function: early diastolic myocardial velocity, the ratio of early diastolic mitral inflow velocity and myocardial velocity, and indexed left atrial dimension. LV diastolic dysfunction was defined as the presence of abnormal values in more than 2 of 3 echocardiographic parameters. The prevalence of LV diastolic dysfunction was higher in the categories with more severe LV hypertrophy. However, LV mass index, rather than relative wall thickness, was a significant determinant of LV diastolic dysfunction, after adjustment for comorbidities. In addition, 71 (10%) out of 740 subjects with normal LV geometric pattern had LV diastolic dysfunction even without obvious LV geometric change. The prevalence of LV diastolic dysfunction was higher in the subjects with more severe LV hypertrophy in a community-based population. Subclinical LV diastolic dysfunction without obvious LV geometric change should be noted and its clinical impact should be elucidated.

Sections du résumé

BACKGROUND
Left ventricular (LV) hypertrophy is reported to cause LV diastolic dysfunction. This study aimed to examine the prevalence of LV diastolic dysfunction in each group categorized by the geometric pattern of LV hypertrophy in a community-based population.
METHODS
We studied 1260 community-dwelling subjects who experienced no symptoms of obvious heart disease (461 men, 799 women) and who participated in annual health check-ups in a rural Japanese community. The subjects were divided into 4 groups according to LV mass index and relative wall thickness: normal geometry, concentric remodeling, eccentric hypertrophy, and concentric hypertrophy. We investigated the prevalence of LV diastolic dysfunction in the overall and stratified population by LV geometric pattern. LV diastolic function was determined by 3 echocardiographic parameters of LV diastolic function: early diastolic myocardial velocity, the ratio of early diastolic mitral inflow velocity and myocardial velocity, and indexed left atrial dimension. LV diastolic dysfunction was defined as the presence of abnormal values in more than 2 of 3 echocardiographic parameters.
RESULTS
The prevalence of LV diastolic dysfunction was higher in the categories with more severe LV hypertrophy. However, LV mass index, rather than relative wall thickness, was a significant determinant of LV diastolic dysfunction, after adjustment for comorbidities. In addition, 71 (10%) out of 740 subjects with normal LV geometric pattern had LV diastolic dysfunction even without obvious LV geometric change.
CONCLUSIONS
The prevalence of LV diastolic dysfunction was higher in the subjects with more severe LV hypertrophy in a community-based population. Subclinical LV diastolic dysfunction without obvious LV geometric change should be noted and its clinical impact should be elucidated.

Identifiants

pubmed: 31813675
pii: S0914-5087(19)30297-7
doi: 10.1016/j.jjcc.2019.09.007
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

439-446

Informations de copyright

Copyright © 2019 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.

Auteurs

Takuya Hasegawa (T)

Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Japan. Electronic address: hasegawa@ncvc.go.jp.

Masanori Asakura (M)

Department of Clinical Medicine and Development, National Cerebral and Cardiovascular Center, Suita, Japan.

Hiroshi Asanuma (H)

Department of Clinical Medicine and Development, National Cerebral and Cardiovascular Center, Suita, Japan.

Makoto Amaki (M)

Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Japan.

Hiroyuki Takahama (H)

Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Japan.

Yasuo Sugano (Y)

Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Japan.

Hideaki Kanzaki (H)

Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Japan.

Satoshi Yasuda (S)

Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Japan.

Toshihisa Anzai (T)

Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Japan.

Chisato Izumi (C)

Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Japan.

Masafumi Kitakaze (M)

Department of Clinical Medicine and Development, National Cerebral and Cardiovascular Center, Suita, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH